- Home
- NRSN vs CALC Comparison
NRSN vs CALC Comparison
Compare NRSN & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRSN
- CALC
- Stock Information
- Founded
- NRSN 2017
- CALC 2011
- Country
- NRSN Israel
- CALC United States
- Employees
- NRSN N/A
- CALC N/A
- Industry
- NRSN Biotechnology: Pharmaceutical Preparations
- CALC Biotechnology: Pharmaceutical Preparations
- Sector
- NRSN Health Care
- CALC Health Care
- Exchange
- NRSN Nasdaq
- CALC Nasdaq
- Market Cap
- NRSN 26.0M
- CALC 20.9M
- IPO Year
- NRSN 2021
- CALC N/A
- Fundamental
- Price
- NRSN $1.22
- CALC $1.91
- Analyst Decision
- NRSN Hold
- CALC Strong Buy
- Analyst Count
- NRSN 1
- CALC 3
- Target Price
- NRSN N/A
- CALC $16.33
- AVG Volume (30 Days)
- NRSN 136.3K
- CALC 33.2K
- Earning Date
- NRSN 06-23-2025
- CALC 05-14-2025
- Dividend Yield
- NRSN N/A
- CALC N/A
- EPS Growth
- NRSN N/A
- CALC N/A
- EPS
- NRSN N/A
- CALC N/A
- Revenue
- NRSN N/A
- CALC N/A
- Revenue This Year
- NRSN N/A
- CALC N/A
- Revenue Next Year
- NRSN N/A
- CALC N/A
- P/E Ratio
- NRSN N/A
- CALC N/A
- Revenue Growth
- NRSN N/A
- CALC N/A
- 52 Week Low
- NRSN $0.51
- CALC $1.43
- 52 Week High
- NRSN $1.50
- CALC $6.02
- Technical
- Relative Strength Index (RSI)
- NRSN 67.14
- CALC 56.52
- Support Level
- NRSN $0.93
- CALC $1.86
- Resistance Level
- NRSN $1.39
- CALC $2.04
- Average True Range (ATR)
- NRSN 0.09
- CALC 0.14
- MACD
- NRSN 0.03
- CALC 0.05
- Stochastic Oscillator
- NRSN 62.59
- CALC 64.79
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
About CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.